FibroBiologics, Inc. Common Stock (FBLG) - Total Liabilities
Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has total liabilities worth $8.62 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
FibroBiologics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See FibroBiologics, Inc. Common Stock short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
FibroBiologics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hansol Homedec
KO:025750
|
Korea | ₩128.30 Billion |
|
BeLive Holdings Ordinary Share
NASDAQ:BLIV
|
USA | $538.91K |
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
USA | $12.38 Million |
|
Quest Resource Holding Corp
NASDAQ:QRHC
|
USA | $109.32 Million |
|
Wilton Resources Inc
V:WIL
|
Canada | CA$668.49K |
|
NanoRepro AG
XETRA:NN6
|
Germany | €694.21K |
|
KONG SUN (BL25000)
F:KOJ5
|
Germany | €2.32 Billion |
|
Castile Resources Ltd
AU:CST
|
Australia | AU$1.02 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down FibroBiologics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FBLG stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 68.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FibroBiologics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of FibroBiologics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $13.71 Million | +29.73% |
| 2024-06-30 | $10.57 Million | +19.82% |
| 2023-06-30 | $8.82 Million | +401.71% |
| 2022-06-30 | $1.76 Million | -- |
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.